Medicure

Medicure(MCUJF)

Barbados - Holetown
Biotechnology
WebsiteLinkedInCareers Page

Focus: Small Molecule

Medicure is a life sciences company focused on Small Molecule.

CardiovascularNephrologyMetabolic Diseases
Funding Stage
PUBLIC
Open Jobs
0

Products & Portfolio (3)

AGGRASTAT
tirofiban
LOE Approaching
INJECTION · SOLUTION
IIb/IIIa receptor, the major platelet surface receptor involved in platelet aggregation. When administered intravenously, AGGRASTAT inhibits ex vivo platelet aggregation in a dose- and concentration-dependent manner. When given according to the PRISM-PLUS regimen of 0.4 mcg/kg/min over 30 minutes followed by a 0.1 mcg/kg/min maintenance infusion, >90% inhibition of platelet aggregation is attained by the end of the 30-minute infusion. When given according to the recommended regimen of 25 mcg/kg followed by a 0.15 mcg/kg/min maintenance infusion, >90% inhibition of platelet aggregation is attained within 10 minutes. Platelet aggregation inhibition is reversible following cessation of the infusion of AGGRASTAT.
rate of thrombotic cardiovascular events (combined endpoint of deathmyocardial infarctionrefractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS)
1998
30
AGGRASTAT
tirofiban
LOE Approaching
INTRAVENOUS · SOLUTION
IIb/IIIa receptor, the major platelet surface receptor involved in platelet aggregation. When administered intravenously, AGGRASTAT inhibits ex vivo platelet aggregation in a dose- and concentration-dependent manner. When given according to the PRISM-PLUS regimen of 0.4 mcg/kg/min over 30 minutes followed by a 0.1 mcg/kg/min maintenance infusion, >90% inhibition of platelet aggregation is attained by the end of the 30-minute infusion. When given according to the recommended regimen of 25 mcg/kg followed by a 0.15 mcg/kg/min maintenance infusion, >90% inhibition of platelet aggregation is attained within 10 minutes. Platelet aggregation inhibition is reversible following cessation of the infusion of AGGRASTAT.
rate of thrombotic cardiovascular events (combined endpoint of deathmyocardial infarctionrefractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS)
1998
30
ZYPITAMAG
pitavastatin magnesium
Peak
ORAL · TABLET
Hydroxymethylglutaryl-CoA Reductase Inhibitors
2017
8

Pipeline & Clinical Trials

N/A
Clinical Trials (1)
NCT07098195To Evaluate the Performance and Safety of RisoR Crest Everolimus Eluting Coronary Stent System
N/A
Phase 1
Clinical Trials (1)
NCT01766154Pharmacokinetic Evaluation of Tirofiban Using a Single High-Dose Bolus In Subjects With Varying Degrees of Renal Function
Phase 1
Short Tirofiban
Myocardial Infarction
Phase 2
Clinical Trials (1)
NCT01522417Shortened Aggrastat® Versus Integrilin in Percutaneous Coronary Intervention
Phase 2
MEND-CABG (MC-1 to Eliminate Necrosis and Damage in Coronary Artery Bypass Graft Surgery)
Coronary Artery Bypass Graft Surgery
Phase 2
Clinical Trials (1)
NCT00157716MEND-CABG (MC-1 to Eliminate Necrosis and Damage in Coronary Artery Bypass Graft Surgery)
Phase 2
pyridoxal-5'-phosphate with and without ACE inhibitor
Diabetes Mellitus Type 2
Phase 2
Clinical Trials (1)
NCT00157729MATCHED (MC-1 and ACE Therapeutic Combination for Hypertensive Diabetics)
Phase 2
Pyridoxal 5'-Phosphate
Tardive Dyskinesia
Phase 2
Clinical Trials (1)
NCT00917293Safety and Efficacy of Pyridoxal 5' -Phosphate in the Treatment of Tardive Dyskinesia
Phase 2
Phase 3
Clinical Trials (1)
NCT01245725Aggrastat Truncated Length Against Standard Therapies in Percutaneous Coronary Intervention
Phase 3
Phase 3
Clinical Trials (1)
NCT04706013Oral Pyridoxal 5'-Phosphate for the Treatment of Patients With PNPO Deficiency
Phase 3
A Safety and Efficacy Study to Confirm the Cardioprotective Effects of MC-1 in Patients Undergoing H
Coronary Artery Bypass Graft Surgery
Phase 3
Clinical Trials (1)
NCT00402506A Safety and Efficacy Study to Confirm the Cardioprotective Effects of MC-1 in Patients Undergoing High-Risk CABG
Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts
Founded: 1997
Portfolio: 3 approved products, 9 clinical trials
Top TAs: Cardiovascular
Portfolio Health
Peak1 (33%)
LOE Approaching2 (67%)
3 total products
Therapeutic Area Focus
Cardiovascular
3 marketed
Marketed
Pipeline